Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers

Eugene F. Schuster (), Elena Lopez-Knowles, Anastasia Alataki, Lila Zabaglo, Elizabeth Folkerd, David Evans, Kally Sidhu, Maggie Chon U. Cheang, Holly Tovey, Manuel Salto-Tellez, Perry Maxwell, John Robertson, Ian Smith, Judith M. Bliss and Mitch Dowsett
Additional contact information
Eugene F. Schuster: The Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research
Elena Lopez-Knowles: The Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research
Anastasia Alataki: The Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research
Lila Zabaglo: UK NEQAS ICC & ISH
Elizabeth Folkerd: The Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research
David Evans: UK NEQAS ICC & ISH
Kally Sidhu: UK NEQAS ICC & ISH
Maggie Chon U. Cheang: The Institute of Cancer Research
Holly Tovey: The Institute of Cancer Research
Manuel Salto-Tellez: Queen’s University Belfast
Perry Maxwell: Queen’s University Belfast
John Robertson: Queen’s Medical Centre
Ian Smith: Royal Marsden Hospital
Judith M. Bliss: The Institute of Cancer Research
Mitch Dowsett: Royal Marsden Hospital

Nature Communications, 2023, vol. 14, issue 1, 1-15

Abstract: Abstract Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given the limited understanding of intrinsic resistance in these tumours, here we conduct a large-scale molecular analysis to identify features that impact on the response of ER + HER2- BC to AI. We compare the 15% of poorest responders (PRs, n = 177) as measured by proportional Ki67 changes after 2 weeks of neoadjuvant AI to good responders (GRs, n = 190) selected from the top 50% responders in the POETIC trial and matched for baseline Ki67 categories. In this work, low ESR1 levels are associated with poor response, high proliferation, high expression of growth factor pathways and non-luminal subtypes. PRs having high ESR1 expression have similar proportions of luminal subtypes to GRs but lower plasma estradiol levels, lower expression of estrogen response genes, higher levels of tumor infiltrating lymphocytes and immune markers, and more TP53 mutations.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-39613-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39613-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-39613-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().